Developer docs
API playgroundTry for free, no card

Search company profiles

MDxHealth

Full company profile

uuid00036i5

Namestring
MDxHealth
Legal namestring
MDxHealth SA
Websiteurl
mdxhealth.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

MDxHealth is a commercial-stage molecular diagnostics company specializing in precision tests for prostate cancer and urologic diseases. Its portfolio includes tissue-based assays (Confirm mdx for detecting occult cancer after negative biopsy, and GPS mdx, the 17-gene Genomic Prostate Score assay for treatment decision support in localized prostate cancer) and liquid-based tests (Exo mdx, an exosomal RNA/protein biomarker test with at-home collection and Level 1 clinical evidence). The company also previously offered Resolve mdx for urinary tract infection diagnosis before discontinuing the product in 2025 following a Medicare recoupment dispute. Technology centers on proprietary gene expression signatures, epigenetic biomarkers, and exosome profiling processed through CAP-accredited, CLIA-certified laboratories in Irvine (CA), Waltham (MA), and Plano (TX).

MDxHealth operates a sales-led go-to-market model, distributing tests through direct enterprise sales representatives targeting urologists, oncologists, and large urology group practices. Physicians order through a dedicated portal (mdxhealthsecure.com), with specimens shipped via FedEx to company labs and results returned for clinical decision-making. Reimbursement is handled by an in-house patient advocate team and revenue cycle management function. Primary customers are practicing urologists and prostate cancer patients, with secondary reach into infectious disease specialists (historically) and academic research collaborations (notably University of Oxford for the GPS-ProMPT study and upcoming ProtecT trial). The company also serves as a partner channel for the ProtecT trial, embedding its test into one of the largest prostate cancer cohorts globally.

Revenue is generated through fee-for-service laboratory testing, recognized when specimens are processed. The company has grown from approximately $22M in 2021 to $107.88M TTM through Q4 2025, with Q4 2025 revenue up 19% YoY and test volumes up 62% (liquid tests specifically up 128%). Management has guided to 27-30% top-line growth for 2026. MDxHealth has funded growth through public equity offerings on NASDAQ ($37M in 2023, $40M in 2024, and a $200M shelf filed in December 2025) and strategic acquisitions, including the Oncotype DX GPS business from Exact Sciences (2022, up to $100M) and Exosome Diagnostics from Bio-Techne (2025, up to $15M). The company is publicly traded on NASDAQ (ticker MDXH), domiciled in Belgium with primary US operations headquartered in Irvine, California.

Short descriptiontext

MDxHealth is a commercial-stage molecular diagnostics company offering tissue-based and liquid biopsy tests, primarily for prostate cancer risk assessment and treatment decision support, serving urologists, oncologists, and prostate cancer patients across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, prostate cancer testing, genomic assays, liquid biopsy, urologic diagnostics
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Molecular Diagnostic Testing Services
TypeOne Time License
Description

MDxHealth generates revenue through laboratory testing services, processing patient specimens (tissue and liquid biopsies) and providing diagnostic results to physicians. Revenue is recognized when tests are performed, with Q4 2025 revenue of $29.5 million representing 19% year-over-year growth.

mdxhealth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Confirm mdx
Description

Prostate cancer test addressing biopsy sampling error and false-negative biopsy dilemma

mdxhealth.com
+4 more records
Core offering1 text field

MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic and genomic tests for prostate cancer and urologic disease assessment. The company operates CAP-accredited, CLIA-certified laboratories in the United States and processes tissue and liquid biopsy specimens sent by physicians, returning risk stratification and treatment guidance results. Core offerings include the tissue-based Confirm mdx and GPS mdx assays, the liquid-biopsy Exo mdx test, and the Resolve mdx urine-based infectious disease test.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 92% six-year freedom-from-failure in active surveillance patients with favorable GPS scores
+2 more records
Product overview1 text field

MDxHealth is a molecular diagnostics company offering a portfolio of genomic and exosome-based diagnostic tests for prostate cancer and other urologic cancers. The company's product portfolio includes Confirm mdx (a gene expression test for prostate cancer risk assessment), GPS mdx (a 17-gene genomic assay acquired from Exact Sciences for prostate cancer aggressiveness scoring), and Exo mdx (an exosome-based liquid biopsy platform). MDxHealth previously offered Resolve mdx for UTI testing, but this product line appears to have been discontinued. All tests are performed in the company's CAP-accredited and CLIA-certified laboratories.

Product and service5 records
1Confirm mdx
CategoryProstate Cancer Diagnostics
Description

A molecular diagnostic test that analyzes gene expression patterns (epigenetic biomarkers) from prostate biopsy tissue to help distinguish between aggressive and indolent prostate cancer, addressing prostate biopsy sampling error and the false-negative biopsy dilemma. Used by urologists and other physicians ordering follow-up testing after a negative biopsy.

2GPS mdx (Genomic Prostate Score)
CategoryProstate Cancer Diagnostics
Description

A 17-gene tissue-based genomic assay that predicts prostate cancer aggressiveness and provides risk scores for metastasis within 10 years and prostate cancer-specific death within 10 years. Designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions. Originally acquired from Exact Sciences as Oncotype DX GPS.

3Exo mdx
CategoryProstate Cancer Diagnostics
Description

A liquid-based prostate cancer test that uses exosome profiling (exosomal RNA and protein biomarkers) from a blood sample to detect and characterize prostate cancer and enhance patient stratification for prostate biopsy decisions. Supports at-home specimen collection and is supported by Level 1 clinical evidence.

4Resolve mdx
CategoryInfectious Disease Diagnostics
Description

A urine-based diagnostic test for infectious disease applications, including urinary tract infection (UTI) detection and pathogen identification. Performed at MDxHealth's CAP-accredited laboratory in Plano, Texas.

5Select mdx
CategoryProstate Cancer Diagnostics
Description

Molecular diagnostic test in the MDxHealth portfolio featuring urine collection, supporting prostate cancer and urologic disease assessment.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Collaboration with Oxford's GPS-ProMPT study demonstrated the prognostic value of the GPS mdx test across 409 patients over six years. MDxHealth announced next phase collaboration with initiation of GPS mdx testing in the landmark UK ProtecT trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

MDxHealth amended its GPS acquisition earnout obligations with Exact Sciences on January 9, 2026, deferring remaining payments into 2026-2028 and issuing warrants for 3 million MDxHealth shares to manage near-term cash obligations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-15
Description

MDxHealth acquired Exosome Diagnostics Inc. from Bio-Techne in September 2025 for up to $15 million, adding the ExoDx test and a CLIA-certified laboratory to its platform. This expanded MDxHealth's prostate cancer diagnostics through liquid-based testing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-02
Description

MDxHealth acquired the Oncotype DX GPS (Genomic Prostate Score) prostate cancer business from Exact Sciences for up to $100 million including cash, stock, and earn-outs. This acquisition significantly strengthened MDxHealth's position in the urology and prostate cancer diagnostic market.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MDxHealth acquired Exact Sciences' Oncotype DX GPS prostate cancer business in 2022 for $100M. Exact Sciences remains a major oncology diagnostics competitor with Cologuard and Oncodetect, and shares the same end customer (urologists/oncologists) and broader precision oncology positioning.

TypeDirect peer
Description

Myriad's Prolaris test directly competes with GPS mdx in prostate cancer treatment-decision risk stratification. Both companies serve urologists with molecular tests designed to guide active surveillance versus treatment decisions.

TypeDirect peer
Description

Natera operates in oncology molecular diagnostics with Signatera (MRD) and Empower (hereditary cancer), targeting similar oncology/urology call points. Its Signatera test is increasingly being studied for prostate cancer, creating direct future overlap with MDxHealth's franchise.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy company focused on oncology. While not currently focused on prostate cancer risk stratification, its liquid biopsy platform (Guardant360, Shield) represents a credible competitive threat as liquid biopsy moves into urology.

TypeBroad incumbent
Description

NeoGenomics provides oncology-focused clinical lab services including molecular and genetic testing, with overlapping sales channels into community oncology and urology practices. Comparable business model as a cancer-focused diagnostic lab services company.

TypeBroad incumbent
Description

Veracyte is a genomic diagnostics company offering tests across urology (Decipher Prostate — a direct competitor to GPS mdx) and other specialty areas. Highly comparable in business model, target end market, and clinical evidence approach.

TypeEmerging player
Description

Castle Biosciences develops molecular diagnostic tests for dermatologic, ocular, and other cancers. Comparable as a small-to-mid-cap specialty molecular diagnostics company targeting physician call points with proprietary gene-expression-based assays.

TypeEmerging player
Description

Biodesix is a specialty diagnostics company offering blood-based lung and other cancer tests. Comparable in business model (small-cap specialty molecular diagnostics with proprietary assays targeting physician offices) but operates in different indications.

TypeBroad incumbent
Description

Opko Health operates clinical laboratories (BioReference) and develops molecular diagnostics, including 4Kscore for prostate cancer risk assessment. Competes directly with MDxHealth's Confirm mdx and Select mdx in the urology call point.

TypeBroad incumbent
Description

Hologic acquired Biotheranostics in 2021, gaining the Prostate Cancer Index (Prolaris competitor) — positioning it as a larger commercial competitor in the prostate cancer molecular diagnostic space where MDxHealth also operates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MDxHealth

Molecular Diagnosticsmdxhealth.com

MDxHealth is a commercial-stage molecular diagnostics company offering tissue-based and liquid biopsy tests, primarily for prostate cancer risk assessment and treatment decision support, serving urologists, oncologists, and prostate cancer patients across the United States.

What MDxHealth does

MDxHealth is a commercial-stage molecular diagnostics company specializing in precision tests for prostate cancer and urologic diseases. Its portfolio includes tissue-based assays (Confirm mdx for detecting occult cancer after negative biopsy, and GPS mdx, the 17-gene Genomic Prostate Score assay for treatment decision support in localized prostate cancer) and liquid-based tests (Exo mdx, an exosomal RNA/protein biomarker test with at-home collection and Level 1 clinical evidence). The company also previously offered Resolve mdx for urinary tract infection diagnosis before discontinuing the product in 2025 following a Medicare recoupment dispute. Technology centers on proprietary gene expression signatures, epigenetic biomarkers, and exosome profiling processed through CAP-accredited, CLIA-certified laboratories in Irvine (CA), Waltham (MA), and Plano (TX).

MDxHealth operates a sales-led go-to-market model, distributing tests through direct enterprise sales representatives targeting urologists, oncologists, and large urology group practices. Physicians order through a dedicated portal (mdxhealthsecure.com), with specimens shipped via FedEx to company labs and results returned for clinical decision-making. Reimbursement is handled by an in-house patient advocate team and revenue cycle management function. Primary customers are practicing urologists and prostate cancer patients, with secondary reach into infectious disease specialists (historically) and academic research collaborations (notably University of Oxford for the GPS-ProMPT study and upcoming ProtecT trial). The company also serves as a partner channel for the ProtecT trial, embedding its test into one of the largest prostate cancer cohorts globally.

Revenue is generated through fee-for-service laboratory testing, recognized when specimens are processed. The company has grown from approximately $22M in 2021 to $107.88M TTM through Q4 2025, with Q4 2025 revenue up 19% YoY and test volumes up 62% (liquid tests specifically up 128%). Management has guided to 27-30% top-line growth for 2026. MDxHealth has funded growth through public equity offerings on NASDAQ ($37M in 2023, $40M in 2024, and a $200M shelf filed in December 2025) and strategic acquisitions, including the Oncotype DX GPS business from Exact Sciences (2022, up to $100M) and Exosome Diagnostics from Bio-Techne (2025, up to $15M). The company is publicly traded on NASDAQ (ticker MDXH), domiciled in Belgium with primary US operations headquartered in Irvine, California.

MDxHealth firmographics

Firmographics
Name
MDxHealth
Legal name
MDxHealth SA
Website
https://mdxhealth.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
251–500 employees
Short description
MDxHealth is a commercial-stage molecular diagnostics company offering tissue-based and liquid biopsy tests, primarily for prostate cancer risk assessment and treatment decision support, serving urologists, oncologists, and prostate cancer patients across the United States.
Ownership category
akta.pro rank

MDxHealth industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular diagnostics
  • Prostate cancer testing
  • Genomic assays
  • Liquid biopsy
  • Urologic diagnostics

Where MDxHealth is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices4 records

Markets served

MDxHealth business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Molecular Diagnostic Testing Services: MDxHealth generates revenue through laboratory testing services, processing patient specimens (tissue and liquid biopsies) and providing diagnostic results to physicians. Revenue is recognized when tests are performed, with Q4 2025 revenue of $29.5 million representing 19% year-over-year growth.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

MDxHealth product offering

Product offering

Core offering

MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic and genomic tests for prostate cancer and urologic disease assessment. The company operates CAP-accredited, CLIA-certified laboratories in the United States and processes tissue and liquid biopsy specimens sent by physicians, returning risk stratification and treatment guidance results. Core offerings include the tissue-based Confirm mdx and GPS mdx assays, the liquid-biopsy Exo mdx test, and the Resolve mdx urine-based infectious disease test.

Product overview

MDxHealth is a molecular diagnostics company offering a portfolio of genomic and exosome-based diagnostic tests for prostate cancer and other urologic cancers. The company's product portfolio includes Confirm mdx (a gene expression test for prostate cancer risk assessment), GPS mdx (a 17-gene genomic assay acquired from Exact Sciences for prostate cancer aggressiveness scoring), and Exo mdx (an exosome-based liquid biopsy platform). MDxHealth previously offered Resolve mdx for UTI testing, but this product line appears to have been discontinued. All tests are performed in the company's CAP-accredited and CLIA-certified laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • Confirm mdx: Prostate cancer test addressing biopsy sampling error and false-negative biopsy dilemma
  • GPS mdx
  • Exo mdx
  • Resolve mdx
  • Select mdx

Products and services

  • Confirm mdx A molecular diagnostic test that analyzes gene expression patterns (epigenetic biomarkers) from prostate biopsy tissue to help distinguish between aggressive and indolent prostate cancer, addressing prostate biopsy sampling error and the false-negative biopsy dilemma. Used by urologists and other physicians ordering follow-up testing after a negative biopsy.
  • GPS mdx (Genomic Prostate Score) A 17-gene tissue-based genomic assay that predicts prostate cancer aggressiveness and provides risk scores for metastasis within 10 years and prostate cancer-specific death within 10 years. Designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions. Originally acquired from Exact Sciences as Oncotype DX GPS.
  • Exo mdx A liquid-based prostate cancer test that uses exosome profiling (exosomal RNA and protein biomarkers) from a blood sample to detect and characterize prostate cancer and enhance patient stratification for prostate biopsy decisions. Supports at-home specimen collection and is supported by Level 1 clinical evidence.
  • Resolve mdx A urine-based diagnostic test for infectious disease applications, including urinary tract infection (UTI) detection and pathogen identification. Performed at MDxHealth's CAP-accredited laboratory in Plano, Texas.
  • Select mdx Molecular diagnostic test in the MDxHealth portfolio featuring urine collection, supporting prostate cancer and urologic disease assessment.

Quantifiable outcome

  • 92% six-year freedom-from-failure in active surveillance patients with favorable GPS scores
  • +2 more outcomes

Companies that use MDxHealth

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

MDxHealth technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MDxHealth partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic and core.

  • University of OxfordstrategicStrategic or Co-development Partner · 16 March 2026Collaboration with Oxford's GPS-ProMPT study demonstrated the prognostic value of the GPS mdx test across 409 patients over six years. MDxHealth announced next phase collaboration with initiation of GPS mdx testing in the landmark UK ProtecT trial.
  • Exact Sciences (GPS Earnout Amendment)coreStrategic or Co-development Partner · 9 January 2026MDxHealth amended its GPS acquisition earnout obligations with Exact Sciences on January 9, 2026, deferring remaining payments into 2026-2028 and issuing warrants for 3 million MDxHealth shares to manage near-term cash obligations.
  • Bio-Techne (Exosome Diagnostics)coreStrategic or Co-development Partner · 15 September 2025MDxHealth acquired Exosome Diagnostics Inc. from Bio-Techne in September 2025 for up to $15 million, adding the ExoDx test and a CLIA-certified laboratory to its platform. This expanded MDxHealth's prostate cancer diagnostics through liquid-based testing capabilities.
  • Exact SciencescoreStrategic or Co-development Partner · 2 August 2022MDxHealth acquired the Oncotype DX GPS (Genomic Prostate Score) prostate cancer business from Exact Sciences for up to $100 million including cash, stock, and earn-outs. This acquisition significantly strengthened MDxHealth's position in the urology and prostate cancer diagnostic market.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

MDxHealth competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: MDxHealth acquired Exact Sciences' Oncotype DX GPS prostate cancer business in 2022 for $100M. Exact Sciences remains a major oncology diagnostics competitor with Cologuard and Oncodetect, and shares the same end customer (urologists/oncologists) and broader precision oncology positioning.
  • Myriad Genetics: Myriad's Prolaris test directly competes with GPS mdx in prostate cancer treatment-decision risk stratification. Both companies serve urologists with molecular tests designed to guide active surveillance versus treatment decisions.
  • Natera: Natera operates in oncology molecular diagnostics with Signatera (MRD) and Empower (hereditary cancer), targeting similar oncology/urology call points. Its Signatera test is increasingly being studied for prostate cancer, creating direct future overlap with MDxHealth's franchise.

Broad incumbents

  • Guardant Health: Guardant Health is a leading liquid biopsy company focused on oncology. While not currently focused on prostate cancer risk stratification, its liquid biopsy platform (Guardant360, Shield) represents a credible competitive threat as liquid biopsy moves into urology.
  • NeoGenomics: NeoGenomics provides oncology-focused clinical lab services including molecular and genetic testing, with overlapping sales channels into community oncology and urology practices. Comparable business model as a cancer-focused diagnostic lab services company.
  • Veracyte: Veracyte is a genomic diagnostics company offering tests across urology (Decipher Prostate — a direct competitor to GPS mdx) and other specialty areas. Highly comparable in business model, target end market, and clinical evidence approach.
  • Opko Health (BioReference Laboratories): Opko Health operates clinical laboratories (BioReference) and develops molecular diagnostics, including 4Kscore for prostate cancer risk assessment. Competes directly with MDxHealth's Confirm mdx and Select mdx in the urology call point.
  • Hologic (post-Biotheranostics): Hologic acquired Biotheranostics in 2021, gaining the Prostate Cancer Index (Prolaris competitor) — positioning it as a larger commercial competitor in the prostate cancer molecular diagnostic space where MDxHealth also operates.

Emerging players

  • Castle Biosciences: Castle Biosciences develops molecular diagnostic tests for dermatologic, ocular, and other cancers. Comparable as a small-to-mid-cap specialty molecular diagnostics company targeting physician call points with proprietary gene-expression-based assays.
  • Biodesix: Biodesix is a specialty diagnostics company offering blood-based lung and other cancer tests. Comparable in business model (small-cap specialty molecular diagnostics with proprietary assays targeting physician offices) but operates in different indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

MDxHealth social profiles

Digital presence

MDxHealth compliance and trust

Trust signal

Compliance3 records

MDxHealth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MDxHealth leadership team

Management profile

Number of profiles

Profiles14 records

MDxHealth subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MDxHealth funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MDxHealth M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MDxHealth

What does MDxHealth do?

MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic and genomic tests for prostate cancer and urologic disease assessment. The company operates CAP-accredited, CLIA-certified laboratories in the United States and processes tissue and liquid biopsy specimens sent by physicians, returning risk stratification and treatment guidance results. Core offerings include the tissue-based Confirm mdx and GPS mdx assays, the liquid-biopsy Exo mdx test, and the Resolve mdx urine-based infectious disease test.

Is MDxHealth a public or private company?

MDxHealth is a public company. It is classified as public and is currently operating.

When was MDxHealth founded?

MDxHealth was founded in 2003. It employs 251 to 500 people.

Where is MDxHealth based?

MDxHealth is headquartered in Irvine, United States, in the North America region.

How does MDxHealth make money?

One revenue line is on record: molecular Diagnostic Testing Services.

Who are MDxHealth's main competitors?

Direct peers on record are Exact Sciences, Myriad Genetics and Natera. Broad incumbents are Guardant Health, NeoGenomics, Veracyte, Opko Health (BioReference Laboratories) and Hologic (post-Biotheranostics). Emerging players are Castle Biosciences and Biodesix.

Does MDxHealth have an API?

No public API is recorded for MDxHealth.

What industry is MDxHealth in?

MDxHealth's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolMDxHealth (MDXH) Q3 2026 Earnings Call TranscriptMDxHealth reported Q3 2026 revenue of $22.7 million, flat year over year, with an operating loss of $8.1 million. The company expects to return to top-line growth in 2027 after a commercial reset following the Resolve UTI discontinuation.The Motley FoolMDxHealth (MDXH) Q3 2026 Earnings Call TranscriptMDxHealth reported Q3 2026 revenue of $22.7 million, flat year over year, with an operating loss of $8.1 million. The company expects to return to top-line growth in 2027 after a commercial reset following the Resolve UTI discontinuation. It plans to roll out AI initiatives in the first half of 2027.Seeking AlphaMDxHealth SA (MDXH) Q3 2026 Earnings Call TranscriptMDxHealth reported Q3 2026 results that fell short of expectations, citing temporary commercial disruption from accelerated sales turnover after Resolve's discontinuation. CEO Michael McGarrity said the commitment to transparency and growth remains unchanged.Business & FinancialMdxhealth Reports Third Quarter 2026 Financial ResultsMDxHealth reported Q3 2026 revenue of $22.7 million, flat year-over-year, with a net loss of $12.3 million, up 26% from the prior year. Adjusted EBITDA was -$6.3 million, and operating expenses rose 16% due to the ExoDx acquisition. The company will host a conference call today.The future of tradingMdxhealth to Release Third Quarter 2026 Financial Results on November 12Mdxhealth announced it will release its third-quarter 2026 financial results after market close on November 12, 2026. The company will also host a conference call with live Q&A at 4:30pm ET on that date.The future of tradingMDxHealth Schedules Third-Quarter 2026 Financial Results ReleaseMDxHealth will release its third-quarter 2026 financial results on November 12, 2026, after market close. A results and corporate update conference call with live Q&A is scheduled for the same day at 4:30 p.m. ET/22:30 CET.Business & FinancialMdxhealth To Release Third Quarter 2026 Financial Results On November 12Mdxhealth will present its third-quarter 2026 financial results and corporate update via conference call and webcast on November 12, 2026, at 4:30pm ET. The call will be accessible via dial-in and webcast, with a replay available afterward.Investing.comMDxHealth stock rating cut to neutral by BTIG on Q3 revenue missBTIG downgraded MDxHealth to Neutral from Buy after the company missed Q3 revenue and suspended 2026 guidance. The stock fell 66% to $0.21, and BTIG removed its $2 price target. MDxHealth is scheduled to report Q3 earnings on November 12.American Banking and Market NewsBTIG Research Reaffirms “Neutral” Rating for MDxHealth (NASDAQ:MDXH)BTIG Research reaffirmed a neutral rating on MDxHealth, while other analysts have mixed ratings. The stock opened at $0.21, with a consensus hold rating and $1.33 target. MDxHealth reported Q2 EPS of -$0.18, beating estimates, with revenue of $27.21 million.American Banking and Market NewsMDxHealth (NASDAQ:MDXH) Rating Lowered to “Hold” at Craig HallumCraig Hallum downgraded MDxHealth from Buy to Hold, while other firms issued mixed ratings. The stock opened at $0.21, with an average analyst target of $1.33 and a consensus EPS estimate of -$0.49 for the year.